Employees with the greatest mental health needs often find themselves navigating a complex disability system. Streamlining their mental health leave and recovery time leads to an overall more productive workforce.
Employees with a severe mental health diagnosis are five times more likely to go on disability leave than their peers. The majority of these employees have difficulty quickly accessing a leave evaluation, further delaying their recovery time and contributing to meaningful loss of productivity for the company.
Hear from Lyra Health’s Medical Clinical Director of Psychiatry, Smita Das, MD, PhD, MPH, and Deborah Olson, Genentech’s Lead Strategist for Well-Being, for a discussion about why it’s crucial for employers to provide streamlined access to disability leave requests as well as high-quality care with Lyra’s new Clinical Leave Evaluation program.
In this webinar replay, you'll learn:
Lead Strategist, Well-Being, Genentech
Medical Director, Psychiatry, Lyra Health
Deborah Olson, Well-being, Lead Strategist at Genentech, a Roche Company, is an ability management strategist with a record of achievement designing and implementing mental wellness programs. She leads the Occupational and Non-Occupational Leave and Disability programs and the Mental Wellness program across Genentech and Roche in the U.S., supporting over 24,000 employees. Prior to joining Genentech, she founded a consulting firm where she supported teams at Kaiser Permanente and Lucile Packard Children’s Hospital at Stanford.
Dr. Das is Board Certified in Psychiatry, Addiction Psychiatry and Addiction Medicine and has over 20 years of research experience in healthcare quality and addiction. She studied Chemistry and Statistics at Stanford, completed her Masters in Public Health at Dartmouth College, and then completed her MD/PhD in Community Health at the University of Illinois at Urbana Champaign. Regionally, she has been a leader in the Northern California Psychiatric Society since 2012 and is now Immediate Past President of the American Psychiatric Association (APA) District Branch. Nationally, she serves on the Council on Addictions at the American Psychiatric Association, has presented to the US Congress and is an invited speaker at conferences. Prior to her position as Medical Director of Psychiatry at Lyra Health, she was Director of Addiction Treatment Services at the Palo Alto VA System. In addition to her work at Lyra, Dr. Das practices in addictions at Stanford School of Medicine where she is a Clinical Assistant Professor.